Claudine Isaacs
Georgetown University · Lombardi Comprehensive Cancer Center · MedStar Georgetown University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Claudine Isaacs as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:07 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03964532 · TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerGeorgetown University · active not recruiting · Breast Cancer · principal investigator
- Ph1NCT03854903 · WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorGeorgetown University · completed · Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer · principal investigator
- Ph1NCT03209401 · Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesGeorgetown University · terminated · Solid Tumor, Adult, Homologous Recombination Deficiency · study chair
- Ph2/Ph3NCT02692755 · Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast CancerGeorgetown University · completed · Hormone Receptor Positive HER-2 Negative Breast Cancer · principal investigator
- Ph1/Ph2NCT01484041 · Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerGeorgetown University · terminated · Breast Cancer · principal investigator
- N/ANCT00898937 · Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the BreastGeorgetown University · terminated · Breast Cancer · principal investigator
- Ph2NCT00661531 · Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine TherapyGeorgetown University · terminated · Breast Cancer, Cancer of the Breast, Neoplasms, Breast · principal investigator
- Ph1/Ph2NCT00217399 · Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast CancerNational Cancer Institute (NCI) · completed · Recurrent Breast Cancer, Stage IV Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA051008 · NCI · GEORGETOWN UNIVERSITY · fiscal years 2019 to 2021 · $62,786 awarded in 2021Grant number is on one of their registry trials
- National Lung Screening Trial (NLST)N1CN25522A- · NCI · GEORGETOWN UNIVERSITY · fiscal years 2007 to 2010 · $604,409 awarded in 2010Same name and institution; not confirmed by an ID
- THE FAMILIAL CANCER REGISTRYM01RR023942 · NCRR · GEORGETOWN UNIVERSITY · fiscal years 2007 to 2009 · $168,344 awarded in 2009Same name and institution; not confirmed by an ID
- CANCER GENETICS NETWORKU24CA078146 · NCI · GEORGETOWN UNIVERSITY · fiscal years 2000 to 2006 · $81,949 awarded in 2006Same name and institution; not confirmed by an ID
- Cancer Genetics Network ovarian cancer screening pilot trial in high risk womenM01RR013297 · NCRR · GEORGETOWN UNIVERSITY · fiscal years 2004 · $191,265 awarded in 2004Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SPORE IN BREAST CANCERP50CA058185 · NCI · GEORGETOWN UNIVERSITY · PI ROBERT B. DICKSON · fiscal years 1992 to 2004Named on NCT00898937
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:07 UTC. The ranking covers the 200 most relevant of 74 PubMed records, and a shared surname and initials can bring in a namesake. All 74 on PubMed
- 1,002 citationsRCR 28.1
- 818 citationsRCR 23.5
- Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.J Natl Cancer Inst · 2012815 citationsRCR 24.2
- 620 citationsRCR 24.3
- 485 citationsRCR 13.0
- Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med · 2016456 citationsRCR 12.7
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet Oncol · 2014390 citationsRCR 10.4
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell · 2021307 citationsRCR 13.7
- Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med · 2016296 citationsRCR 7.8
- 267 citationsRCR 11.0